{"id":"W4224433803","doi":"10.1016/s1474-4422(22)00143-0","title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":110,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Biogen","keywords":"Natalizumab; Medicine; Progressive multifocal leukoencephalopathy; Multiple sclerosis; Clinical endpoint; Dosing; Relapsing remitting; Randomized controlled trial; Neurology; Pediatrics; Physical therapy; Internal medicine; Immunology; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001938511,0.002186321,0.004451026,0.0004506183,0.000492848,0.001328632,0.001576475,0.003063369,0.009770821],"category_scores_gemma":[0.003214789,0.0008467783,0.003234787,0.0003954245,0.001404793,0.002171359,0.0005014036,0.005045325,0.00181419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001002522,"about_ca_system_score_gemma":0.0009051998,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001756352,"about_ca_topic_score_gemma":0.002334961,"domain_scores_codex":[0.998787,0.0006153579,0.00008236554,0.0002563107,0.00006591801,0.0001929634],"domain_scores_gemma":[0.9982148,0.0007532376,0.0003023298,0.0001697894,0.0000856552,0.0004740864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.990624,0.002179996,0.0001583852,0.0001848219,0.0004555221,0.00001482225,0.00003261551,0.0001501027,0.0006432909,0.00004170091,0.0002075855,0.00530732],"study_design_scores_gemma":[0.9521224,0.04524136,0.001312298,0.00003080747,0.0003185166,0.00001975615,0.00002311571,0.0004081873,0.0001422785,0.0001533056,0.0002112082,0.00001676334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990743,0.003218175,0.0005061216,0.0007437211,0.001058677,0.00119216,0.000663006,0.0001294019,0.001745712],"genre_scores_gemma":[0.9918293,0.001292927,0.001065401,0.0008191149,0.0004721993,0.001433989,0.0005839299,0.00003200532,0.002471044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009770821,"threshold_uncertainty_score":0.03268659,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09327933621658352,"score_gpt":0.3429768786919041,"score_spread":0.2496975424753206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}